Bottom line is...can the management of OWCP improv
Post# of 15624
...can we get PR on clinical activity during, as well as "end results"? What about personnel changes within the academic research hospitals that might affect the way our clinical trials are run/reported on?
...can our new CFO relay any positive info on securing lines of credit/favorable financing possibilities?
...can Pharmitbe share how they are progressing with the placebo for psoriasis phase 2 clinical?
Release of info pertaining to any of the above could possibly improve share price and jeopardize shorters...not greedy either, but my head is sore from hitting the wall lately regarding management's apparent disregard to shareholders.